ESMO 2019: Invited Discussant: The CARD Trial – Cabazitaxel as Third Line Therapy in Metastatic Castration-Resistant Prostate Cancer
Barcelona, Spain (UroToday.com) In this discussion of the CARD trial of cabazitaxel as third line therapy in metastatic castration-resistant prostate cancer (mCRPC), Silke Gillessen, MD, began by laying out the therapeutic landscape of mCRPC, using this imagery to highlight what happens after up-front anti-androgen therapy and docetaxel chemotherapy, because it is less clear what the […]